Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas

Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significant increase in research directed towards identifying potential biomarkers that can be used to diagnose and provide prognostic information for pancreatic cancer. These markers can be used clinically to optimize and personalize therapy for individual patients. In this review, we focused on 3 biomarkers involved in the DNA damage response pathway and the necroptosis pathway: Chromodomainhelicase-DNA binding protein 5, chromodomain-helicaseDNA binding protein 7, and mixed lineage kinase domain-like protein. The aim of this article is to review present literature provided for these biomarkers and current studies in which their effectiveness as prognostic biomarkers are analyzed in order to determine their future use as biomarkers in clinical medicine. Based on the data presented, these biomarkers warrant further investigation,and should be validated in future studies.

miR-24-3p靶向CHD5影响甲状腺癌细胞迁移能力、侵袭能力和放射敏感性

目的探讨miR-24-3p调控染色体质域解螺旋酶DNA结合蛋白5(CHD5)表达对甲状腺癌细胞迁移能力、侵袭能力和放射敏感性的影响。方法选取2018年9月—2020年9月杭州市萧山区第一人民医院首次确诊为甲状腺癌的患者125例,收集其癌组织和癌旁组织(距肿瘤边缘>4 cm)和相关临床病理资料。选取人正常甲状腺细胞系Nthy-ori 3-1和人甲状腺癌细胞系KTC1、SW579、TPC-1。检测癌组织、癌旁组织和4种细胞中miR-24-3p、CHD5蛋白的表达。对SW579细胞分别转染miR-24-3p抑制物anti-miR-24-3p(anti-miR-24-3p组)和阴性对照物anti-miR-NC(anti-miR-NC组)、miR-24-3p模拟物miR-24-3p mimics(miR-24-3p mimics组)和阴性对照物miR-NC(miR-NC组)、共转染anti-miR-24-3p和si-NC(anti-miR-24-3p+si-NC组)、共转染anti-miR-24-3p和si-CHD5(anti-miR-24-3p+si-CHD5组)。分析各组细胞的迁移能力、增殖能力和放射敏感性。采用双荧光素酶报告基因实验验证miR-24-3p与CHD5的靶向关系。结果癌组织和甲状腺癌细胞系KTC1、SW579、TPC-1中miR-24-3p相对表达量均显著高于癌旁组织和正常甲状腺细胞系Nthy-ori 3-1(P<0.05),CHD5蛋白相对表达量均显著低于癌旁组织和正常甲状腺细胞系Nthy-ori 3-1(P<0.05)。SW579细胞miR-24-3p相对表达量最高,CHD5蛋白相对表达量最低。有无淋巴转移、不同临床分期的甲状腺癌患者之间miR-24-3p和CHD5蛋白表达差异有统计学意义(P<0.001)。抑制miR-24-3p表达可抑制SW579细胞的迁移能力和侵袭能力,并提高SW579细胞的放射敏感性(P<0.05);miR-24-3p靶向负调控CHD5的表达;沉默CHD5可逆转抑制miR-24-3p表达对SW579细胞迁移、侵袭和放射敏感性的影响(P<0.05)。结论抑制miR-24-3p表达可上调CHD5,进而抑制SW579细胞的迁移能力和侵袭能力,提高其放射敏感性。

Long non-coding RNA DPP10-AS1 represses the proliferation and invasiveness of glioblastoma by regulating miR-24-3p/CHD5 signaling pathway

This investigation aimed to unveil new prospective diagnosis-related biomarkers together with treatment targets against glioblastoma.Methods:The expression levels of long non-coding RNA(lncRNA)DPP10-AS1 were assessed using real-time quantitative polymerase chain reaction(RT-qPCR)within both the patient tissue specimens and glioblastoma cell lines.The relationship between lncRNA DPP10-AS1 expression in glioblastoma and patient prognosis was investigated.Cell Counting Kit-8(CCK-8),transwell,and clonogenic experiments were utilized to assess tumor cells’proliferation,invasiveness,and migratory potentials after lncRNA DPP10-AS1 expression was up or down-regulated.Using an online bioinformatics prediction tool,the intracellular localization of lncRNA DPP10-AS1 and its target miRNA were predicted,and RNA-FISH verified results.A dual-luciferase reporter experiment validated the relationship across miR-24-3p together with lncRNA DPP10-AS1.MiR-24-3p expression within glioblastoma was identified through RT-qPCR,and potential link across miR-24-3p and lncRNA DPP10-AS1 was assessed using Pearson correlation analysis.Moreover,influence from lncRNA DPP10-AS1/miR-24-3p axis upon glioblastoma cell progression was assessed in vivo via a subcutaneous xenograft tumor model.Results:The expression of lncRNA DPP10-AS1 was notably reduced in both surgical specimens of glioblastoma and the equivalent cell lines.Low level of lncRNA DPP10-AS1 in glioblastoma is following poor prognosis.The downregulation of lncRNA DPP10-AS1 in glioblastoma cells resulted in enhanced cellular proliferation,migration,and invasion capabilities,accompanied by downregulated E-cadherin and upregulated vimentin and N-cadherin.Additionally,the observed upregulation of lncRNA DPP10-AS1 demonstrated a substantial inhibitory function upon proliferation,invasion,and migratory capabilities of LN229 cells.Subcellular localization disclosed that lncRNA DPP10-AS1 had a binding site that interacted with miR-24-3p.Upregulated miR-24-3p was detected in glioblastomas,displaying an inverse correlation with lncRNA DPP10-AS1 expression.MiR-24-3p downstream target has been determined as chromodomain helicase DNA binding protein 5(CHD5).LncRNA DPP10-AS1 affected the invasion and proliferation of glioblastoma by controlling the miR-24-3p/CHD5 axis.Conclusion:The present study demonstrated that lncRNA DPP10-AS1 can inhibit the invasive,migratory,and proliferative properties of glioblastoma by regulating the miR-24-3p/CHD5 signaling pathway.Consequently,lncRNA DPP10-AS1 has potential as a tumor suppressor and might be utilized for accurate diagnosis and targeted treatments of glioblastomas.

CHD5基因在食管癌中的表观遗传学改变

目的:研究食管癌发病过程中染色质解旋酶DNA结合蛋白5(Chromodomain helicase DNA-binding protein5,CHD5)基因表观遗传学改变,探讨CHD5基因甲基化作为食管癌诊断标志物的可行性.方法:用甲基化特异性聚合酶链反应(methylation specific PCR,MSP)检测72例食管癌组织及成对癌旁组织,9例正常食管黏膜组织及4株食管癌细胞系中CHD5基因的甲基化状态,并用逆转录聚合酶链式反应(RT-PCR)检测CHD5基因在上述食管癌细胞系的表达.结果:69%(50/72)食管癌组织发生CHD5基因启动子区甲基化,32%(23/72)癌旁组织发生甲基化,差异具有统计学意义(χ2=20.254,P<0.05).9例食管正常组织未发生甲基化,2株食管癌细胞系中由于基因启动子区甲基化导致CHD5基因表达缺失,经5-aza-deoxycytidine处理96h后CHD5重新表达.结论:食管癌中CHD5基因频繁发生甲基化,表观遗传学改变是其基因表达的重要调节机制,CHD5基因甲基化有可能作为食管癌诊断的标志物.

CHD5和WWOX基因在胃癌中的表达及其对预后的影响

目的:探讨抑癌基因CHD5和WWOX的蛋白在胃癌中的表达及其对预后的影响。方法:随机选取我院收治的胃癌患者65例,采用免疫组化法检测胃癌组织及相应癌旁组织CHD5和WWOX蛋白的表达及与预后的关系。结果:CHD5和WWOX蛋白在胃癌组织中的阳性表达率分别为36.92%(24/65)和41.54%(27/65),明显低于在癌旁组织的(P<0.05)。在胃癌组织中,CHD5和WWOX蛋白的表达与TNM分期、肿瘤分化程度及淋巴结转移均有关(P<0.05)。生存分析KaplanMeier法显示,CHD5和WWOX蛋白阳性表达的患者1、3年生存率显著高于阴性表达的患者,差异均有统计学意义(P<0.05)。结论:CHD5和WWOX在胃癌组织中低表达与胃癌的病变程度、侵袭转移及预后不良关系密切,提示CHD5和WWOX蛋白低表达可能参与胃癌的发生、发展及胃黏膜恶性转变等过程。

CHD5与KLF5蛋白在胃癌组织中的表达及其与预后的关系

目的:探讨胃癌组织中CHD5和KLF5的表达意义及其与预后的关系.方法:收集2000-01/2007-06在昆明医学院第二附属医院手术切除的208例胃癌组织标本,采用免疫组织化学SP法检测胃腺癌组织、癌旁组织中CHD5和KLF5的表达;采用χ2检验和Fisher精确概率法分析胃癌中CHD5和KLF5的表达与临床病理指标的相关性;采用Cox比例风险模型方法进行多因素分析;应用Kaplan-Meier生存分析法判断CHD5和KLF5表达与各临床病理参数及其预后的关系.结果:胃癌组织中CHD5和KLF5呈明显低表达特点.其中,CHD5的表达与患者年龄、肿瘤分化程度、浸润深度、TNM分期、淋巴结和远处转移等有关,差异有统计学意义(P<0.05);KLF5的表达与肿瘤分化程度、浸润深度、TNM分期、淋巴结和远处转移等有关,差异有统计学意义(P<0.05).多因素分析显示,患者的生存时间主要受患者性别、肿瘤部位、组织分化程度、远处转移、TNM分期、CHD5和KLF5的异常表达等因素影响;Kaplan-Meier生存分析显示,CHD5、KLF5阴性组的中位生存期分别为(21.00mo±1.36mo)、(20.00mo±1.54mo),而CHD5、KLF5阳性组的中位生存期分别为(55.00mo±6.97mo)、(45.00mo±3.27mo).CHD5和KLF5阴性表达组患者的1、3年生存率明显低于阳性表达患者,差异均有统计学意义.结论:胃癌组织中CHD5和KLF5低表达与胃癌的侵袭转移及不良预后存在相关性.提示CHD5和KLF5蛋白的异常表达可能参与胃黏膜恶性转变以及胃癌发生发展等生物学过程.

CRISPR/Cas9敲除CHD5基因促进前列腺癌细胞增殖

染色质域解旋酶DNA结合蛋白5(chromodomain helicase DNA binding protein 5,CHD5)是人类肿瘤中一个重要的抑癌基因,是肿瘤抑制网络的控制开关,但是它在前列腺癌发生发展中的作用却少有研究。本研究利用CRISPR/Cas9技术敲除前列腺癌细胞PC-3中CHD5基因,探索敲除CHD5基因对PC-3细胞增殖能力的影响。研究根据CRISPR/Cas9靶点设计规则设计了3组特异性sgRNA,连接到pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro质粒构建表达载体。测序鉴定后将重组表达载体转染293T细胞包装慢病毒。包装慢病毒滴度分别为CHD5-sgRNA-17.84×10^9 TU/mL,CHD5-sgRNA-25.83×10^9 TU/mL,CHD5-sgRNA-35.23×10^9 TU/mL。用CHD5-sgRNA慢病毒感染PC-3细胞,嘌呤霉素筛选阳性细胞,Western印迹检测CHD5蛋白的表达水平,CCK-8、克隆形成实验以及细胞周期检测对PC-3细胞增值能力的影响。Western印迹结果显示,CHD5-sgRNA-1组CHD5蛋白质水平无明显变化,CHD5-sgRNA-2组和CHD5-sgRNA-3组CHD5蛋白质表达水平显著低于空白组和阴性对照组,成功获得稳定敲除CHD5基因的PC-3细胞系,其中感染CHD5-sgRNA-2的PC-3细胞中CHD5蛋白水平最低,用于后续研究。CCK-8结果显示,敲除CHD5促进PC-3细胞的增殖能力。空白组、阴性对照组以及CHD5-gRNA-2组的克隆数分别为(32.50±1.50)、(35.33±2.02)和(50.83±4.25)。细胞周期分析结果显示,G2/M期细胞分别为(7.56±0.59)%、(8.33±0.61)%和(27.21±1.04)%,差异均有统计学意义(P<0.01)。Western印迹证实,CHD5敲除后,G2/M期周期相关蛋白质细胞周期蛋白B1、cdc25C和cdc2的表达量增加,phospho-cdc25C、phospho-cdc2以及p21的表达水平下降(P<0.05)。以上结果表明,CHD5敲除的PC-3细胞系构建成功,CHD5表达缺失通过上调细胞周期蛋白B1、去磷酸化cdc25C、cdc2以及下调p21表达促进前列腺癌PC-3细胞增殖。

人色素域解旋酶DNA结合蛋白5的基因克隆及其真核表达载体的构建

目的:克隆人色素域解旋酶DNA结合蛋白5(chromodomain helicase DNA-binding protein5,CHD5)基因并构建真核表达载体。方法:应用PCR扩增人CHD5基因的编码区,使用基因重组方法构建真核细胞表达载体peGFPc1-CHD5,实时定量PCR技术检测重组质粒peGFPc1-CHD5转染293T工具细胞后的过表达能力。结果:经过PCR方法,有效扩增了CHD5基因编码区,构建了peGFPc1-CHD5真核细胞表达质粒,测序分析表明所克隆的CHD5基因编码区序列无误。实时定量PCR检测结果表明重组质粒peGFPc1-CHD5能有效地过表达CHD5基因。结论:成功地构建了人CHD5的真核细胞表达载体peGFPc1-CHD5,并在293T工具细胞中实现过表达,为进一步研究奠定了实验基础。